Latigo Biotherapeutics, Inc.’s Quiet Period Set To End Tomorrow (NASDAQ:LTGO)

Posted by Geri Gentry on Sep 15th, 2026

Latigo Biotherapeutics’ (NASDAQ:LTGO – Get Free Report) quiet period will end on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its IPO on August 7th. The total size of the offering was $345,600,000 based on an initial share price of $18.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

Several analysts have recently commented on LTGO shares. Jefferies Financial Group initiated coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price target on the stock. The Goldman Sachs Group started coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price for the company. Guggenheim started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen lowered Latigo Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, Leerink Partners assumed coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Latigo Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $52.25.

View Our Latest Report on LTGO

Latigo Biotherapeutics Price Performance

Latigo Biotherapeutics stock opened at $22.64 on Tuesday. Latigo Biotherapeutics has a 1 year low of $17.22 and a 1 year high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last posted its quarterly earnings data on Thursday, September 3rd. The company reported ($27.59) earnings per share for the quarter.

Insider Buying and Selling at Latigo Biotherapeutics

In other news, major shareholder Foresite Capital Management V, acquired 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This represents a 7.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James B. Tananbaum bought 140,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the director owned 2,008,024 shares in the company, valued at $36,144,432. This represents a 7.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Latigo Biotherapeutics

(Get Free Report)

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions.